Hansoh reports Phase 3 success for GSK‑partnered ADC in SCLC as FDA clears Sanofi on‑body injector
Hansoh announced that its Phase 3 trial of the antibody‑drug conjugate Ris‑Rez met the primary endpoint in patients with small cell lung cancer. The study was conducted in partnership with GSK and the positive result supports continued development of the candidate.
The U.S. Food and Drug Administration granted approval for Sanofi’s on‑body injector, a wearable device designed to deliver medication subcutaneously. The clearance enables the product to enter the U.S. market.
The briefing also referenced additional updates on Huntington’s disease research, developments at Fate Therapeutics, and news from Bausch + Lomb, though no further details were provided.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that